JPRN-UMIN000037054Recruiting未知
The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis. - The study of efficacy of lenvatinib in patients with hepatocellular carcinoma(HCC): Multicenter analysis.
Yokohama City University Medical Center0 sites250 target enrollmentStarted: June 13, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 250
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to 90years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Clinically significant ascites (refractory ascites requiring drainage) 2)Esophageal varices with the potential to bleed 4)Brain tumor 5)On dialysis 6)Gastrointestinal hemorrhage during past month 7)Active multiple cancer 8)Any of the following concurrent diseases: Grade 3 or greater arrhythmia or poorly controlled hypertension according to the JCOG/JSCO Japanese translation of the NCI Common Terminology Criteria for Adverse Events v 4.0 (CTCAE v 4.0) 9)Orally taking an herbal medicine approved for the treatment of cancer (e.g., shosaikoto) 10)Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) related disease 11) Pregnant or nursing 12) Otherwise found ineligible as a subject by the researcher
Investigators
Similar Trials
Recruiting
Unknown
Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective studynresectable advanced or recurrent thymic carcinomaJPRN-UMIN000051645Graduate School of Medicine, Chiba University80
Completed
Not Applicable
The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approvalHepatocellular carcinomaJPRN-UMIN000034333ational Hospital Organization Kyoto Medical Center500
Active, not recruiting
Phase 1
A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.EUCTR2015-001467-39-ITGETNE (GRUPO ESPAñOL DE TUMORES NEUROENDOCRINOS)110
Completed
Phase 2
A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial)colorectal cancerJPRN-UMIN000023446ational Cancer Center30
Recruiting
Not Applicable
Evaluation of lorlatinib efficacy of patients with EML4-ALKALK positive lung cancerJPRN-UMIN000042617Japanese Society of Lung Cancer150